

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (previously presented) A method for the treatment of a disorder of the eye comprising: administering to a subject a therapeutically effective amount of a composition comprising a dsRNA between 21 and 23 nucleotides in length and a carrier, said dsRNA having a nucleotide sequence corresponding to mRNA of a target gene expressed in the eye; said administering of the composition occurring outside the blood-retina barrier, and said composition inhibiting the target gene by RNA interference inside the eye.
- 2.-3. (canceled)
4. (previously presented) The method of claim 1, wherein said disorder is related to angiogenesis and/or neovascularization.
5. (previously presented) The method of claim 1, wherein said disorder is related to the retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.
6. (previously presented) The method of claim 1, wherein said disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.
- 7.-8. (canceled)
9. (previously presented) The method of claim 1, wherein said dsRNA is an inhibitor of expression of the target gene.
10. (previously presented) The method of claim 9, wherein said inhibitor inhibits expression of the target gene involved in angiogenesis and/or neovascularization.
- 11.-15. (canceled)
16. (previously presented) The method of claim 1, wherein the dsRNA comprises a terminal 3'-hydroxyl group.
- 17.-18. (canceled)
19. (previously presented) The method of claim 1, wherein said target gene comprises SEQ ID NO: 3.

20.-93 (canceled)

94. (withdrawn) The method of claim 1, further comprising preparing the dsRNA.

95. (withdrawn) The method of claim 1, further comprising diagnosing a subject with a disorder or a predisposition to a disorder of the eye.

96. (previously presented) The method of claim 1, further comprising detecting a product of the target gene.

97. (withdrawn) The method of claim 1, further comprising isolating the target gene.

98. (previously presented) The method of claim 1, wherein said administering is by systemic administration.